ProPhase Labs, Inc. (PRPH)
USD 0.32
(4.0%)
USD 0.32
(4.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 44.38 Million USD | -63.81% |
| 2022 | 122.64 Million USD | 55.17% |
| 2021 | 79.04 Million USD | 444.59% |
| 2020 | 14.51 Million USD | 46.96% |
| 2019 | 9.87 Million USD | -24.76% |
| 2018 | 13.12 Million USD | 33.03% |
| 2017 | 9.86 Million USD | -53.05% |
| 2016 | 21.01 Million USD | 1.99% |
| 2015 | 20.6 Million USD | -6.64% |
| 2014 | 22.07 Million USD | -11.83% |
| 2013 | 25.03 Million USD | 11.72% |
| 2012 | 22.4 Million USD | 28.38% |
| 2011 | 17.45 Million USD | 20.35% |
| 2010 | 14.5 Million USD | -26.82% |
| 2009 | 19.81 Million USD | -3.37% |
| 2008 | 20.5 Million USD | -48.05% |
| 2007 | 39.47 Million USD | -6.29% |
| 2006 | 42.12 Million USD | -21.49% |
| 2005 | 53.65 Million USD | 22.09% |
| 2004 | 43.94 Million USD | 5.9% |
| 2003 | 41.49 Million USD | 41.05% |
| 2002 | 29.42 Million USD | 19.26% |
| 2001 | 24.66 Million USD | 27.4% |
| 2000 | 19.36 Million USD | -21.92% |
| 1999 | 24.8 Million USD | -31.87% |
| 1998 | 36.4 Million USD | -48.15% |
| 1997 | 70.2 Million USD | 8675.0% |
| 1996 | 800 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.47 Million USD | -31.92% |
| 2024 Q1 | 3.63 Million USD | 3.86% |
| 2023 Q1 | 19.3 Million USD | -11.55% |
| 2023 Q4 | 3.49 Million USD | -58.17% |
| 2023 FY | 44.38 Million USD | -63.81% |
| 2023 Q3 | 8.36 Million USD | -36.71% |
| 2023 Q2 | 13.21 Million USD | -31.53% |
| 2022 FY | 122.64 Million USD | 55.17% |
| 2022 Q4 | 21.82 Million USD | -9.82% |
| 2022 Q3 | 24.2 Million USD | -16.82% |
| 2022 Q2 | 29.09 Million USD | -38.79% |
| 2022 Q1 | 47.53 Million USD | 5.26% |
| 2021 Q4 | 45.15 Million USD | 376.74% |
| 2021 FY | 79.04 Million USD | 444.59% |
| 2021 Q2 | 9.14 Million USD | -40.13% |
| 2021 Q1 | 15.27 Million USD | 195.78% |
| 2021 Q3 | 9.47 Million USD | 3.61% |
| 2020 Q4 | 5.16 Million USD | 34.45% |
| 2020 Q1 | 1.88 Million USD | -39.89% |
| 2020 Q3 | 3.84 Million USD | 5.99% |
| 2020 Q2 | 3.62 Million USD | 91.9% |
| 2020 FY | 14.51 Million USD | 46.96% |
| 2019 Q4 | 3.14 Million USD | 13.56% |
| 2019 FY | 9.87 Million USD | -24.76% |
| 2019 Q3 | 2.76 Million USD | 67.53% |
| 2019 Q2 | 1.65 Million USD | -28.77% |
| 2019 Q1 | 2.31 Million USD | -43.37% |
| 2018 Q2 | 3.18 Million USD | -6.49% |
| 2018 FY | 13.12 Million USD | 33.03% |
| 2018 Q1 | 3.4 Million USD | -17.92% |
| 2018 Q3 | 2.43 Million USD | -23.45% |
| 2018 Q4 | 4.09 Million USD | 67.81% |
| 2017 Q3 | 3.04 Million USD | 59.58% |
| 2017 Q2 | 1.9 Million USD | 147.08% |
| 2017 Q4 | 4.15 Million USD | 36.55% |
| 2017 Q1 | 771 Thousand USD | -89.87% |
| 2017 FY | 9.86 Million USD | -53.05% |
| 2016 Q3 | 5.18 Million USD | 82.23% |
| 2016 Q2 | 2.84 Million USD | -46.98% |
| 2016 Q4 | 7.6 Million USD | 46.67% |
| 2016 Q1 | 5.37 Million USD | -34.22% |
| 2016 FY | 21.01 Million USD | 1.99% |
| 2015 Q4 | 8.16 Million USD | 85.95% |
| 2015 Q3 | 4.39 Million USD | 100.37% |
| 2015 Q1 | 5.86 Million USD | -34.69% |
| 2015 FY | 20.6 Million USD | -6.64% |
| 2015 Q2 | 2.19 Million USD | -62.61% |
| 2014 FY | 22.07 Million USD | -11.83% |
| 2014 Q1 | 6.17 Million USD | -35.73% |
| 2014 Q2 | 1.79 Million USD | -70.88% |
| 2014 Q3 | 5.13 Million USD | 185.48% |
| 2014 Q4 | 8.97 Million USD | 74.89% |
| 2013 Q3 | 5.94 Million USD | 206.81% |
| 2013 Q2 | 1.93 Million USD | -74.29% |
| 2013 Q1 | 7.54 Million USD | -16.93% |
| 2013 FY | 25.03 Million USD | 11.72% |
| 2013 Q4 | 9.6 Million USD | 61.41% |
| 2012 Q3 | 5.41 Million USD | 185.9% |
| 2012 Q1 | 6.01 Million USD | -19.34% |
| 2012 Q4 | 9.07 Million USD | 67.66% |
| 2012 Q2 | 1.89 Million USD | -68.53% |
| 2012 FY | 22.4 Million USD | 28.38% |
| 2011 Q3 | 5.08 Million USD | 191.46% |
| 2011 Q1 | 3.16 Million USD | -48.87% |
| 2011 Q2 | 1.74 Million USD | -44.91% |
| 2011 FY | 17.45 Million USD | 20.35% |
| 2011 Q4 | 7.46 Million USD | 46.78% |
| 2010 Q1 | 1.97 Million USD | -78.3% |
| 2010 Q3 | 5.2 Million USD | 360.12% |
| 2010 FY | 14.5 Million USD | -26.82% |
| 2010 Q4 | 6.19 Million USD | 18.99% |
| 2010 Q2 | 1.13 Million USD | -42.76% |
| 2009 Q2 | 1.74 Million USD | -56.16% |
| 2009 FY | 19.81 Million USD | -3.37% |
| 2009 Q1 | 3.98 Million USD | -41.19% |
| 2009 Q4 | 9.1 Million USD | 82.92% |
| 2009 Q3 | 4.97 Million USD | 184.75% |
| 2008 Q4 | 6.77 Million USD | 6.68% |
| 2008 Q3 | 6.35 Million USD | 207.23% |
| 2008 Q1 | 5.3 Million USD | -60.9% |
| 2008 Q2 | 2.06 Million USD | -61.01% |
| 2008 FY | 20.5 Million USD | -48.05% |
| 2007 Q3 | 11.84 Million USD | 137.31% |
| 2007 FY | 39.47 Million USD | -6.29% |
| 2007 Q1 | 9.07 Million USD | -36.05% |
| 2007 Q2 | 4.98 Million USD | -45.04% |
| 2007 Q4 | 13.56 Million USD | 14.59% |
| 2006 Q3 | 11.48 Million USD | 85.7% |
| 2006 FY | 42.12 Million USD | -21.49% |
| 2006 Q4 | 14.19 Million USD | 23.65% |
| 2006 Q2 | 6.18 Million USD | -39.78% |
| 2006 Q1 | 10.26 Million USD | -42.13% |
| 2005 Q1 | 11.75 Million USD | -33.79% |
| 2005 Q2 | 8.84 Million USD | -24.75% |
| 2005 FY | 53.65 Million USD | 22.09% |
| 2005 Q3 | 15.31 Million USD | 73.22% |
| 2005 Q4 | 17.74 Million USD | 15.8% |
| 2004 Q3 | 9.69 Million USD | 40.42% |
| 2004 Q1 | 9.6 Million USD | -41.4% |
| 2004 Q2 | 6.9 Million USD | -28.15% |
| 2004 Q4 | 17.75 Million USD | 83.17% |
| 2004 FY | 43.94 Million USD | 5.9% |
| 2003 Q4 | 16.39 Million USD | 65.36% |
| 2003 Q2 | 7 Million USD | -14.49% |
| 2003 Q3 | 9.91 Million USD | 41.51% |
| 2003 FY | 41.49 Million USD | 41.05% |
| 2003 Q1 | 8.19 Million USD | -16.04% |
| 2002 Q2 | 5.72 Million USD | 1.25% |
| 2002 Q4 | 9.75 Million USD | 17.85% |
| 2002 Q3 | 8.27 Million USD | 44.49% |
| 2002 Q1 | 5.65 Million USD | -33.66% |
| 2002 FY | 29.42 Million USD | 19.26% |
| 2001 Q3 | 6.72 Million USD | 101.3% |
| 2001 FY | 24.66 Million USD | 27.4% |
| 2001 Q1 | 4.8 Million USD | -37.48% |
| 2001 Q2 | 3.33 Million USD | -30.48% |
| 2001 Q4 | 8.52 Million USD | 26.86% |
| 2000 Q4 | 7.68 Million USD | 104.08% |
| 2000 FY | 19.36 Million USD | -21.92% |
| 2000 Q3 | 3.76 Million USD | 189.61% |
| 2000 Q2 | 1.3 Million USD | -80.35% |
| 2000 Q1 | 6.61 Million USD | -47.08% |
| 1999 FY | 24.8 Million USD | -31.87% |
| 1999 Q1 | 6.1 Million USD | -64.33% |
| 1999 Q2 | 2.1 Million USD | -65.57% |
| 1999 Q3 | 4.1 Million USD | 95.24% |
| 1999 Q4 | 12.5 Million USD | 204.88% |
| 1998 Q4 | 17.1 Million USD | 59.81% |
| 1998 Q1 | 7.3 Million USD | -75.0% |
| 1998 Q3 | 10.7 Million USD | 723.08% |
| 1998 FY | 36.4 Million USD | -48.15% |
| 1998 Q2 | 1.3 Million USD | -82.19% |
| 1997 Q1 | 22.2 Million USD | 442.79% |
| 1997 Q4 | 29.2 Million USD | 98.64% |
| 1997 Q2 | 4 Million USD | -81.98% |
| 1997 FY | 70.2 Million USD | 8675.0% |
| 1997 Q3 | 14.7 Million USD | 267.5% |
| 1996 FY | 800 Thousand USD | 0.0% |
| 1996 Q4 | 4.09 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alvotech | 91.43 Million USD | 51.458% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 12.255% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 92.169% |
| Journey Medical Corporation | 79.18 Million USD | 43.946% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 61.848% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 90.442% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -84.221% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -84.221% |
| SCYNEXIS, Inc. | 140.14 Million USD | 68.329% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -2201.481% |
| Alpha Teknova, Inc. | 36.68 Million USD | -20.99% |
| Cosmos Health Inc. | 53.37 Million USD | 16.848% |
| Bright Green Corporation | 401.49 Thousand USD | -10954.793% |
| Dynavax Technologies Corporation | 232.28 Million USD | 80.892% |
| Embecta Corp. | 1.12 Billion USD | 96.04% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 90.883% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 93.424% |
| PainReform Ltd. | - USD | -Infinity% |
| Safety Shot Inc | 202.67 Thousand USD | -21799.64% |
| Procaps Group, S.A. | 409.92 Million USD | 89.173% |
| Theratechnologies Inc. | 81.76 Million USD | 45.717% |
| Harrow Health, Inc. | 130.19 Million USD | 65.909% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -248.52% |
| Biofrontera Inc. | 34.07 Million USD | -30.269% |
| DURECT Corporation | 8.54 Million USD | -419.233% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 92.694% |
| Cronos Group Inc. | 88.84 Million USD | 50.041% |
| OptiNose, Inc. | 70.98 Million USD | 37.476% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 89.975% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -581.45% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 89.753% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -262.361% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -12.215% |
| Radius Health, Inc. | 2.88 Billion USD | 98.46% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -37.375% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 95.639% |
| Procaps Group S.A. | 409.92 Million USD | 89.173% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -3308.909% |
| Viatris Inc. | 15.42 Billion USD | 99.712% |
| Rockwell Medical, Inc. | 83.61 Million USD | 46.917% |
| Aytu BioPharma, Inc. | 81 Million USD | 45.206% |
| SIGA Technologies, Inc. | 139.91 Million USD | 68.278% |
| Tilray Brands, Inc. | 788.94 Million USD | 94.374% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 65.396% |
| Shineco, Inc. | 9.8 Million USD | -352.812% |
| PetIQ, Inc. | 1.1 Billion USD | 95.972% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -369766.667% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 97.648% |
| Alimera Sciences, Inc. | 80.75 Million USD | 45.038% |
| Silver Spike Investment Corp. | 11.72 Million USD | -278.634% |
| Assertio Holdings, Inc. | 152.06 Million USD | 70.813% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -662.299% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -154.831% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -4023.355% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -58.724% |
| Hempacco Co., Inc. | 4.04 Million USD | -997.083% |
| Talphera, Inc. | 651 Thousand USD | -6717.819% |
| Alvotech | 91.43 Million USD | 51.458% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 85.981% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 96.576% |
| Currenc Group, Inc. | 53.25 Million USD | 16.658% |
| Kamada Ltd. | 144.75 Million USD | 69.339% |
| Indivior PLC | 1.09 Billion USD | 95.939% |
| Evoke Pharma, Inc. | 5.18 Million USD | -756.73% |
| Flora Growth Corp. | 76.07 Million USD | 41.655% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -4023.355% |
| Evolus, Inc. | 202.08 Million USD | 78.037% |
| HUTCHMED (China) Limited | 837.99 Million USD | 94.704% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 93.112% |
| Akanda Corp. | 2.16 Million USD | -1954.765% |